TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury
Brief Summary: Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.


Options:
A: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension
B: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: EPVent; Type: EXPERIMENTAL; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Transpulmonary pressure-directed ventilation (EPVent) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Low tidal volume ventilation | Intervention Type: PROCEDURE; Name: Placement of an esophageal balloon measurements; Assigned to Arm(s): Control, EPVent | Intervention Type: OTHER; Name: Low tidal volume ventilation; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Transpulmonary pressure-directed ventilation (EPVent); Assigned to Arm(s): EPVent
D: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Efficacy and Safety Comparison of Insulin Detemir vs. NPH Insulin in Children and Adolescents Diagnosed With Type 1 Diabetes
Brief Summary: This trial is conducted in Europe.

The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insulin detemir or NPH insulin once or twice daily as basal insulin. Additionally you will receive insulin aspart as bolus insulin


Options:
A: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: NPH insulin; Type: EXPERIMENTAL; Interventions: Drug: insulin NPH, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): NPH insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): NPH insulin, insulin detemir
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin /insulin isophane | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: insulin levemir / aspart | Intervention Type: DRUG; Name: insulin levemir / aspart; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: human insulin /insulin isophane; Assigned to Arm(s): 1
C: Arm Label: IDeg OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: IGlar OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IGlar OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD, IGlar OD
D: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): insulin detemir

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Life 2: Improving Fitness and Function in Elders
Brief Summary: The purpose of this study is to determine whether a 12-month physical activity counseling program, compared to usual care, improves physical performance in a sample of older veterans. The primary physical performance outcome is change in gait speed.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multi-component physical activity counseling program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multi-component physical activity counseling program; Assigned to Arm(s): Arm 1
C: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
D: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is uncertainty about the optimal diet in the prevention and treatment of diabetes type 2. Earlier studies have generally focused on intakes of fat, protein, carbohydrate, fiber, fruit and vegetables. This study is based on another approach which compares foods that were available during human evolution with more recently introduced ones. The basic tenet from evolutionary biology is that if human physiology is less adapted to a relatively recently introduced diet based on agriculture, this could cause disturbances to human physiology and ultimately lead to diseases. Epidemiological studies indicates that diabetes mellitus type 2 is absent or near absent in populations eating a Palaeolithic ("Old Stone Age") diet which is free from food items produced in agriculture or the food industry. Our study hypothesis is that a Palaeolithic diet is better than the standard diabetes diet recommended today in treating diabetes type 2.

Fifteen patients with diabetes type 2 have been randomized to

1. a Palaeolithic diet based on lean meat, fish, fruit, vegetables, root vegetables, eggs, and nuts
2. a standard diabetes diet as recommended by national health authorities.

The patients eat the diet they have been randomized to for three months and then switches to the other diet for another three months. The study is conducted in Primary Health Care stations.


Options:
A: Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight.; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Virtual Coach software | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Activity monitor and website | Intervention Type: OTHER; Name: Virtual Coach software; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Activity monitor and website; Assigned to Arm(s): Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema
Brief Summary: Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.


Options:
A: Arm Label: RePneu Lung Volume Reduction Coil System; Type: EXPERIMENTAL; Interventions: Device: RePneu Lung Volume Reduction Coil System | Arm Label: Control arm is standard medical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: RePneu Lung Volume Reduction Coil System; Assigned to Arm(s): RePneu Lung Volume Reduction Coil System
B: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC) | Intervention Type: DEVICE; Name: Control; Assigned to Arm(s): Control
C: Arm Label: BLVR Treatment; Type: EXPERIMENTAL; Interventions: Biological: BLVR Treatment | Intervention Type: BIOLOGICAL; Name: BLVR Treatment; Assigned to Arm(s): BLVR Treatment
D: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema
Brief Summary: Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8 subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.


Options:
A: Arm Label: BLVR Treatment; Type: EXPERIMENTAL; Interventions: Biological: BLVR Treatment | Intervention Type: BIOLOGICAL; Name: BLVR Treatment; Assigned to Arm(s): BLVR Treatment
B: Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery
C: Arm Label: Treatment plus Optimal Medical Therapy; Type: EXPERIMENTAL; Interventions: Device: InterVapor® treatment plus Optimal Medical Therapy | Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal Medical Therapy | Intervention Type: DEVICE; Name: InterVapor® treatment plus Optimal Medical Therapy; Assigned to Arm(s): Treatment plus Optimal Medical Therapy | Intervention Type: OTHER; Name: Optimal Medical Therapy; Assigned to Arm(s): Optimal Medical Therapy
D: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Exhale® Drug-Eluting Stent | Intervention Type: DEVICE; Name: Exhale® Drug-Eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham control; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Provider and Peer Delivered Youth Smoking Intervention
Brief Summary: The purpose of this study was to determine whether a pediatric practice-based smoking prevention and cessation intervention increases abstinence rates among adolescents.


Options:
A: Arm Label: "Intervention" group; Type: EXPERIMENTAL; Interventions: Behavioral: TABADO program | Arm Label: "Control" group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TABADO program; Assigned to Arm(s): "Intervention" group
B: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CBST | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + CBST; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Pediatric Practice-Based Smoking Intervention; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children
Brief Summary: The purpose of this study is to determine whether semi-annual fluoride varnish applications combined with caregiver counseling are effective in preventing and reducing a severe form of dental decay, known as early childhood caries, in native and non-native children aged 6 months to 5 years.


Options:
A: Arm Label: COHS administered fluoride varnish and oral health education; Type: EXPERIMENTAL; Interventions: Device: Fluoride varnish, Behavioral: Oral health education | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Dental services delivered by the Indian Health Service. | Intervention Type: DEVICE; Name: Fluoride varnish; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: BEHAVIORAL; Name: Oral health education; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: OTHER; Name: Dental services delivered by the Indian Health Service.; Assigned to Arm(s): Usual care
B: Intervention Type: DRUG; Name: Fluoride varnish; Assigned to Arm(s): N/A
C: Arm Label: Precision Family Spirit; Type: EXPERIMENTAL; Interventions: Behavioral: Precision Family Spirit | Arm Label: Standard Family Spirit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Family Spirit | Intervention Type: BEHAVIORAL; Name: Precision Family Spirit; Assigned to Arm(s): Precision Family Spirit | Intervention Type: BEHAVIORAL; Name: Standard Family Spirit; Assigned to Arm(s): Standard Family Spirit
D: Arm Label: Little Holy One intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules | Arm Label: Nutrition control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active nutrition control | Intervention Type: BEHAVIORAL; Name: Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules; Assigned to Arm(s): Little Holy One intervention | Intervention Type: BEHAVIORAL; Name: Active nutrition control; Assigned to Arm(s): Nutrition control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children
Brief Summary: The purpose of this study is to determine whether semi-annual fluoride varnish applications combined with caregiver counseling are effective in preventing and reducing a severe form of dental decay, known as early childhood caries, in native and non-native children aged 6 months to 5 years.


Options:
A: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
B: Intervention Type: DRUG; Name: Fluoride varnish; Assigned to Arm(s): N/A
C: Arm Label: Early treatment; Type: EXPERIMENTAL; Interventions: Other: comprehensive dental treatment | Arm Label: Regualr treatment; Type: NO_INTERVENTION; Interventions: Other: Only emergency dental treatment | Intervention Type: OTHER; Name: comprehensive dental treatment; Assigned to Arm(s): Early treatment | Intervention Type: OTHER; Name: Only emergency dental treatment; Assigned to Arm(s): Regualr treatment
D: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Intervention Program "Obeldicks" for Obese Children and Adolescents
Brief Summary: The intervention program "Obeldicks" was developed for obese children aged 6 to 16 years. This intervention is gender- and age specific. The 12-months intervention is based on nutrition course, behaviour therapy and exercise therapy. The evaluation compromised quality of structure, process and results of the intervention. Primary outcome measure is change of weight status as standard deviation score of BMI. Furthermore, cardiovascular risk factor profile, hormones (e.g. iGF-I, thyroid hormones, vitamin D status)adipocytokines, GI- hormones, intima media thickness are measured prior to and after the one-year intervention. The changes of these hormones and adipocytokines will allow to answer the questions whether the alterations of these hormones are a cause or consequence of overweight. Additionally, a genetic screening is performed to characterize the participants to probably predict response to intervention.


Options:
A: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
B: Arm Label: Reduced Glycemic Load Diet; Type: OTHER; Interventions: Dietary Supplement: Reduced Glycemic Load Diet | Arm Label: Standard Diet; Type: OTHER; Interventions: Dietary Supplement: Standard Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Reduced Glycemic Load Diet; Assigned to Arm(s): Reduced Glycemic Load Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard Diet; Assigned to Arm(s): Standard Diet
C: Intervention Type: BEHAVIORAL; Name: obesity intervention; Assigned to Arm(s): N/A
D: Arm Label: Lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orlistat/Meal Replacement/Lifestyle Modification | Arm Label: Oral Contraceptives (OCP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Loestrin 1/20 | Arm Label: Lifestyle/OCP Combined; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination of treatments | Intervention Type: DRUG; Name: Orlistat/Meal Replacement/Lifestyle Modification; Assigned to Arm(s): Lifestyle intervention | Intervention Type: DRUG; Name: Loestrin 1/20; Assigned to Arm(s): Oral Contraceptives (OCP) | Intervention Type: DRUG; Name: Combination of treatments; Assigned to Arm(s): Lifestyle/OCP Combined

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome
Brief Summary: Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B